NEUROShield™ is an artificial intelligence based clinical decision support tool

which provides volumetric analysis to understand the mechanism of disease,

tracking clinical progression of disease and helps in monitoring the effects of
the treatment. It provides clinicians with objective analysis to aid with patient's
assessments and supports the clinical impression with quantitative analysis.

VOLUMETRIC ANALYSIS OF BRAIN STRUCTURE

1. HIPPOCAMPUS
Alzhiemer's | Dementia | Epilepsy

2. WHOLE BRAIN
Movement disorders | Parkinsonism
Dementia | Huntington’s Disease

3. VENTRICLES
Alzhiemers | Dementia | Epilepsy
Hydrocephalus

L
4. MIDBRAIN, PONS, AND BRAINSTEM
Dementia | Parkinsonism
Pontine Supranuclear Palsy
FEATURES
• Fully automated segmentation for brain & its sub-structures
• Micro-ethnicity based specific reference ranges
• AI enabled clinical decision support
• Condition specific analysis
• Focused structrual volumetric analysis

BENEFITS
• IAbsolute volume of multiple structures
• IIndividual specific analysis (normalised to ICV%)
• IDetection of <5% atrophy
• IProvides detailed analysis of atrophy and lateralization
• IAdvanced visualizations of regions of interest

CLINICAL ADVANTAGES
Diagnostic support tool for neurodegenerative conditions by
obtaining precise volumetric brain data by using 3D structural MRI.

Improving the diagnostic and prognostic capabilities for

neurodegenerative conditions.

Leveraging AI to fully automate the tedious task of manual image

processing and deliver results with industry leading accuracy.
 WHAT CUSTOMERS SAY…

Neuroshield enables structural analysis and assessment of

Cerebral Atrophy in patients. It gives an analysis of localised
brain atrophy relative to that of the Indian (healthy controls)
references. This enables earlier MCI (mild cognitive impairment)
detection and eliminates the possibility of over or under
estimation while quantifying atrophy.

SENIOR NEUROSURGEON,
Super-specialty Hospital, Pune, India

While a traditional 2D MRI image reading provides only a limited

understanding of mild atrophy changes, NeuroShield provides
quantitative support for diagnosis based on visualization and
volumetric analysis of 3D MRI images. This analysis helps me in
assessing conditions like MCI, dementia (AD), MS, epilepsy, and TBI
more efficiently and arrive at optimal evidence-based clinical
decisions.

CONSULTING NEUROLOGIST,
550 Bedded Multi-Speciality Hospital, New Delhi, India

IN-MED PROGNOSTICS AUSTRALIA PTY LTD

ABN: 91642475170, PO Box 60, Hurstville BC NSW 1481, Australia.

nat.iyer@in-medprognostics.com +61 423 383 446 www.in-medprognostics.com

@in-med-prognostics @Inmedprognostics @NEURO_SHIELD